美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

三倍做多標普生物-Direxion

252.23

+1.830.73%

成交量：7.31萬

成交額：1,869.16萬

市值：4.98億

市盈率：- -

高：259.40

開：255.78

低：250.92

收：250.40

52周最高：341.93

52周最低：76.29

股本：197.45萬

流通股本：197.45萬

量比：1.91

換手率：3.70%

股息：1.00

股息率：0.40%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

醫療保健板塊市場快訊

醫療健康板塊綜述：市場動態快報

人保健康天津分公司因欺騙投保人被罰28萬元一人被終身禁業

ELANCO公司的新世界螺旋蠅藥物獲得FDA緊急批准。

胡偉獲批擔任人保健康董事

和諧健康保險孝感中支被罰18萬，涉編制虛假資料

醫療保健板塊市場快訊匯總

把腫瘤變成「原位疫苗」!Replimune(REPL.US)溶瘤病毒闖過FDA，PD-1耐藥黑色素瘤迎來新一代免疫重啓方案

北京經濟技術開發區：鼓勵具身智能、自動駕駛、醫療健康等重點領域數據交易流通每年發放1億元數據券

醫療保健板塊市場動態綜述

醫療板塊市場動態速覽

構建社保商保分層協同機制，破解創新藥支付困境——商業醫療保險與創新藥支付管理研討會在京召開

Moderna研發的首款mRNA流感疫苗獲FDA批准

莫德納首款mRNA流感疫苗獲FDA批准

莫德納首款mRNA流感疫苗獲FDA批准

环球市场播报

武田製藥Orzeyful獲FDA批准，用於治療1型發作性睡病

醫療保健板塊動態：市場快評

醫療保健板塊快訊：市場動態一覽

醫療保健板塊動態：市場快評

醫療保健板塊動態：市場快評

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/LABU/news?page=10"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多標普生物-Direxion","latestPrice":252.23,"timestamp":1789568744580,"preClose":250.4,"halted":0,"volume":73050,"delay":0,"changeRate":0.007308306709265112,"floatShares":1974486,"shares":1974486,"eps":0,"marketStatus":"交易中","change":1.83,"latestTime":"09-16 10:26:18 EDT","open":255.78,"high":259.395,"low":250.92,"amount":18691643.1825,"amplitude":0.033846,"askPrice":253.3,"askSize":30,"bidPrice":252.32,"bidSize":100,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":250.4,"sharesOutstanding":3074486,"nav":268.659,"aum":530464172.89,"dividendRate":0.003971,"bidAskSpread":0.003539,"preHourTrading":{"tag":"盘前","latestPrice":254.8128,"preClose":250.4,"latestTime":"09:28 EDT","volume":4289,"amount":1082884.5326099999,"timestamp":1789565312693,"change":4.4128,"changeRate":0.017623,"amplitude":0.012511},"postHourTrading":{"tag":"盘后","latestPrice":251.98,"preClose":250.4,"latestTime":"19:59 EDT","volume":8108,"amount":2036460.6035,"timestamp":1789516773600,"change":1.58,"changeRate":0.00631,"amplitude":0.00631},"volumeRatio":1.912646,"impliedVol":0.923,"impliedVolPercentile":0.5378},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":1974486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.912646,"shares":1974486,"dividePrice":1.0016,"high":259.395,"amplitude":0.033846,"preClose":250.4,"low":250.92,"week52Low":76.29,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":252.23,"committee":0.538462,"eps":0,"divideRate":0.003971,"volume":73050,"delay":0,"ttmEps":0,"open":255.78,"prevYearClose":159.39,"prevWeekClose":261.3,"prevMonthClose":296.31,"prevQuarterClose":292.1,"fiveDayClose":279.02,"twentyDayClose":289.98,"sixtyDayClose":230.01},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:10,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1183021512","title":"醫療保健板塊市場快訊","url":"https://stock-news.laohu8.com/highlight/detail?id=1183021512","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183021512?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 04:55","pubTimestamp":1786136134,"startTime":"0","endTime":"0","summary":"她认为该交易按当前方案完成的可能性为75%，但鉴于Jamieson的“优质资产”属性、在加拿大的领先市场份额，以及预计至2028年收入复合年增长率达11%，存在25%的可能性出现更高报价。消息公布后，TD将目标股价从48加元上调至49加元，以反映概率加权结果，但将评级从“买入”下调至“持有”。该股盘中上涨9.6%，报45.47加元。** 欧洲斯托克600指数上涨0.2%，软件和医疗保健板块领涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","XLV","BK4588","BK4585","XBI","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145080185","title":"醫療健康板塊綜述：市場動態快報","url":"https://stock-news.laohu8.com/highlight/detail?id=1145080185","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145080185?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 00:23","pubTimestamp":1786119809,"startTime":"0","endTime":"0","summary":"她在报告中坦言，“对报价未达预期感到惊讶”。该分析师认为，按当前方案完成交易的概率为75%，但同时存在25%的可能性，因Jamieson具备“优质资产”属性、在加拿大市场占据领先份额，且预计至2028年收入复合年增长率达11%，报价有望被上调。消息公布后，TD将目标股价从48加元上调至49加元，以反映概率加权结果，同时将评级从“买入”下调至“持有”。该股现涨9.6%，报45.47加元。泛欧斯托克600指数上涨0.2%，软件与医疗健康板块领涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4581","BK4588","BK4585","LABU","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657649773","title":"人保健康天津分公司因欺騙投保人被罰28萬元 一人被終身禁業","url":"https://stock-news.laohu8.com/highlight/detail?id=2657649773","media":"金融一线","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657649773?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 21:36","pubTimestamp":1786109760,"startTime":"0","endTime":"0","summary":"8月7日金融一线消息，国家金融监督管理总局天津监管局行政处罚信息公开表显示，中国人民健康保险股份有限公司天津分公司因欺骗投保人，被罚款28万元。闻伟被禁止终身进入保险业。序号当事人名称主要违法违规行为行政处罚内容作出决定机关1中国人民健康保险股份有限公司天津分公司欺骗投保人。对中国人民健康保险股份有限公司天津分公司罚款28万元；对闻伟禁止终身进入保险业国家金融监督管理总局天津监管局","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jryx/fd/2026-08-07/doc-inimnzse9955329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4581","XBI","BK4588","XLV","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657646475","title":"ELANCO公司的新世界螺旋蠅藥物獲得FDA緊急批准。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657646475","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657646475?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 21:03","pubTimestamp":1786107806,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657643444","title":"胡偉獲批擔任人保健康董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2657643444","media":"金融一线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657643444?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 20:09","pubTimestamp":1786104540,"startTime":"0","endTime":"0","summary":"8月7日金融一线消息，国家金融监督管理总局发布《关于胡伟中国人民健康保险股份有限公司董事任职资格的批复》，核准胡伟中国人民健康保险股份有限公司董事的任职资格。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jryx/hm/2026-08-07/doc-inimnzsm4704005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK4588","LABU","BK4581","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657617229","title":"和諧健康保險孝感中支被罰18萬，涉編制虛假資料","url":"https://stock-news.laohu8.com/highlight/detail?id=2657617229","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657617229?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 18:58","pubTimestamp":1786100322,"startTime":"0","endTime":"0","summary":"蓝鲸新闻8月7日讯，近日，孝感金融监管分局发布行政处罚决定书，剑指和谐健康保险股份有限公司孝感中心支公司及相关责任人。罚单显示，和谐健康保险股份有限公司孝感中心支公司的主要违法违规行为是：编制虚假资料。针对上述违法行为，孝感金融监管分局对和谐健康保险股份有限公司孝感中心支公司罚款18万元，对李婷警告并罚款2.5万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1786096518804106658","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["XLV","BK4585","LABU","XBI","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129560773","title":"醫療保健板塊市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1129560773","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129560773?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 16:22","pubTimestamp":1786090970,"startTime":"0","endTime":"0","summary":"投资者在美国就业数据和中东局势谈判消息出炉前保持观望态度。泛欧斯托克600指数微涨0.2%，软件与医疗保健板块领涨。伦敦富时100指数同样小幅上扬0.2%，国际油价企稳带动石油巨头走强。帝亚吉欧延续涨势，股价已连续第二个交易日攀升，目前涨幅达1.5%。软件巨头SAP攀升3.5%，但戴姆勒卡车控股公司在发布财报后下跌2.9%。意大利富时MIB指数基本持平，而西班牙IBEX 35指数因银行股走弱而微跌0.3%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","BK4588","XBI","XLV","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657904156","title":"把腫瘤變成「原位疫苗」!Replimune(REPL.US)溶瘤病毒闖過FDA，PD-1耐藥黑色素瘤迎來新一代免疫重啓方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2657904156","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657904156?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 14:59","pubTimestamp":1786085956,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","LU1169590202.USD","BK4139","LU1169589451.USD","PD","REPL","BK4585","BK4588","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657965566","title":"北京經濟技術開發區：鼓勵具身智能、自動駕駛、醫療健康等重點領域數據交易流通 每年發放1億元數據券","url":"https://stock-news.laohu8.com/highlight/detail?id=2657965566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657965566?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 12:34","pubTimestamp":1786077245,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","DRIV","NBDS","FDIF","XBI","BK4585","FAI","KOMP","MOTO","ROBT","BK4588","XT","CARZ","IQM","BK4581","HAIL","IXJ","VHT","TARK","BK4550","WDRN","XLV","IDRV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160721676","title":"醫療保健板塊市場動態綜述","url":"https://stock-news.laohu8.com/highlight/detail?id=1160721676","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160721676?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 00:25","pubTimestamp":1786033543,"startTime":"0","endTime":"0","summary":"0739 ET - 伦敦上市制药商Hikma Pharmaceuticals上半年业绩表现强劲，但其对全年业绩的展望却显得颇为保守，并未随之上调，这令市场感到意外。这一积极表现主要得益于Hikma旗下品牌药部门的强劲增长，预计将受到投资者的欢迎。然而，即便上半年核心运营利润率大幅改善，Hikma仍坚持其2026年全年核心运营利润指引，即7.2亿至7.7亿美元，这一区间与市场普遍预期的7.31亿美元相比，并未显得更为乐观。受此消息影响，公司股价大涨10%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4585","LABU","BK4588","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137064261","title":"醫療板塊市場動態速覽","url":"https://stock-news.laohu8.com/highlight/detail?id=1137064261","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137064261?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 16:26","pubTimestamp":1786004808,"startTime":"0","endTime":"0","summary":"1655 GMT - 礼来公司CEO David Ricks在CNBC上表示，该公司近期推出的每日一次GLP-1口服药Foundayo，尽管定价更低，但正在扩大市场而非蚕食现有市场。与此同时，减肥治疗的覆盖面持续扩大，进一步拓宽了潜在市场总规模。这些利好因素增强了礼来公司的信心，使其将营收预期从820亿至850亿美元上调至850亿至870亿美元。礼来股价目前上涨3%。市场对GLP-1减肥药的持续强劲需求推动第二季度营收跃升48%，达到229.7亿美元，超出预期的206.9亿美元。诺和诺德股价下跌4%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4581","XBI","BK4588","BK4585","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657669688","title":"構建社保商保分層協同機制，破解創新藥支付困境——商業醫療保險與創新藥支付管理研討會在京召開","url":"https://stock-news.laohu8.com/highlight/detail?id=2657669688","media":"金融一线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657669688?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 14:55","pubTimestamp":1785999300,"startTime":"0","endTime":"0","summary":"专题：新浪健康保险研究院2026年7月31日，由中央财经大学保险学院主办、新浪健康保险研究院协办的“商业医疗保险与创新药支付管理研讨会”在京举行。因此，在医保基金收支承压、商业保险资金池有限、天价药风险集中的现实约束下，造成创新药支付困境凸显。商保在创新药上市早期的支付补充价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxyy/2026-08-06/doc-inimkfvm3890828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","LABU","BK4585","BK1574","MEDX","LNGR","BK1161","BK4588","XBI","XLV","IBBQ","BK4581","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657232501","title":"Moderna研發的首款mRNA流感疫苗獲FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2657232501","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657232501?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 13:20","pubTimestamp":1785993606,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4585","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657917506","title":"莫德納首款mRNA流感疫苗獲FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2657917506","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657917506?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 11:44","pubTimestamp":1785987861,"startTime":"0","endTime":"0","summary":"来源：环球市场播报美国食品药品管理局批准了莫德纳针对50岁及以上成人的mRNA流感疫苗。这款名为mFlusiva的疫苗采用了与莫德纳新冠疫苗相同的mRNA技术。今年2月，FDA最初直接拒绝审查莫德纳的申请。莫德纳对FDA 2月份的决定感到意外。几天后，莫德纳提出了一份包含另一项试验的修订计划，FDA随后改变了立场。即使获得FDA批准，该疫苗的商业前景依然存在不确定性。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2026/08/06114458030151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657051935","title":"莫德納首款mRNA流感疫苗獲FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2657051935","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657051935?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 11:09","pubTimestamp":1785985740,"startTime":"0","endTime":"0","summary":"美国食品药品管理局批准了莫德纳针对50岁及以上成人的mRNA流感疫苗。这款名为mFlusiva的疫苗采用了与莫德纳新冠疫苗相同的mRNA技术。今年2月，FDA最初直接拒绝审查莫德纳的申请。莫德纳对FDA 2月份的决定感到意外。几天后，莫德纳提出了一份包含另一项试验的修订计划，FDA随后改变了立场。即使获得FDA批准，该疫苗的商业前景依然存在不确定性。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-06/doc-inimivfi3151001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657220495","title":"武田製藥Orzeyful獲FDA批准，用於治療1型發作性睡病","url":"https://stock-news.laohu8.com/highlight/detail?id=2657220495","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657220495?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 03:55","pubTimestamp":1785959722,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","TAK","BK4007","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198057342","title":"醫療保健板塊動態：市場快評","url":"https://stock-news.laohu8.com/highlight/detail?id=1198057342","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198057342?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 00:29","pubTimestamp":1785947351,"startTime":"0","endTime":"0","summary":"最新医疗保健板块市场快讯，本报道仅在道琼斯通讯社于美东时间4:20、12:20及16:50独家发布。0429 ET - 伯恩斯坦分析师指出，诺和诺德第二季度财报表现超预期，并上调了业绩指引，但这对市场普遍预期的中值调整幅度微乎其微。Wegovy口服药的销售额低于市场预期，但公司强调，差异源于去库存行为。在哥本哈根，诺和诺德在财报公布后下跌4.4%。该股持平于1.06林吉特。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","LABU","PMDE","BK4581","XBI","JOYT","VOTE","XLV","DECU","GXDW","VGFPF","RGLO","FEBU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176091087","title":"醫療保健板塊快訊：市場動態一覽","url":"https://stock-news.laohu8.com/highlight/detail?id=1176091087","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176091087?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 16:28","pubTimestamp":1785918487,"startTime":"0","endTime":"0","summary":"0736 GMT - 杰富瑞分析师在一份研究报告中指出，德国医疗保健集团费森尤斯正上调全年盈利指引，这得益于其Kabi制药部门增长驱动力的盈利能力提升。分析师表示，费森尤斯旗下Kabi业务在第二季度实现了17%的调整后营业利润率，其增长向量的利润率首次进入17%至19%的区间。此外，分析人士认为，德国医疗保健改革的获批，为集团旗下Helios医院部门消除了监管不确定性。费森尤斯股价上涨5.6%。在哥本哈根，诺和诺德在公布财报后下跌4.4%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGLO","LABU","FEBU","DECU","XLV","GXDW","BK4585","BK4581","JOYT","VGFPF","VOTE","BK4588","XBI","PMDE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151299937","title":"醫療保健板塊動態：市場快評","url":"https://stock-news.laohu8.com/highlight/detail?id=1151299937","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151299937?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:57","pubTimestamp":1785877040,"startTime":"0","endTime":"0","summary":"1038 ET - 摩根大通分析师指出，葛兰素史克新近推出的药物，将是降低这家英国药企明年前景风险的关键。葛兰素史克近期推出了血癌药物Blenrep和哮喘治疗药物Exdensur，而通过收购Nuvalent获得的肺癌药物Jideytro，也在上月获得美国批准。0123 ET - 摩根大通分析师在一份研究报告中表示，费森尤斯医疗第二季度业绩超出市场预期，但该公司重申全年业绩指引，暗示未来几个季度盈利可能收缩。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4585","BK4581","XLV","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122423549","title":"醫療保健板塊動態：市場快評","url":"https://stock-news.laohu8.com/highlight/detail?id=1122423549","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122423549?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 00:26","pubTimestamp":1785860812,"startTime":"0","endTime":"0","summary":"**GSK新品上市，能否化解明年风险？GSK近期推出了血癌药物Blenrep和哮喘治疗药Exdensur，而通过收购Nuvalent获得的肺癌药物Jideytro，上月也已获得美国批准。0123 ET - 摩根大通分析师在研报中表示，费森尤斯医疗第二季度业绩超出市场预期，但公司重申全年指引，暗示未来几个季度盈利可能收缩。这家德国透析专科公司公布的季度调整后营业利润为5.69亿欧元，高于市场普遍预期的5.14亿欧元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","XBI","BK4585","LABU","BK4581","XLV"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}